UPDATE: This press release has been updated to remove a duplicate table.

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a provider of virtual primary care and pharmacy services, reported financial results for the second quarter ended June 30, 2026.

Second-quarter 2026 revenue was $47.3 million, within the Company’s guidance range of $47 million to $50 million. Adjusted EBITDA loss was approximately $3.5 million, improving approximately 21% sequentially. Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies, and with the guidance provided today, the Company said it believes it is effectively at the end of its transition away from compounded GLP-1 medications.

Gross margin expanded approximately 280 basis points from the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and continued scaling of the Company’s in-house pharmacy. Weight Management Program subscribers increased to approximately 108,000 at quarter end, while total active subscribers rose 20% year over year to approximately 356,000.

The Company said Women’s Health operating trends continue to improve, supported by lower customer acquisition costs and a broad set of new pharmacy products scheduled to launch in the second half. LifeMD also launched an exclusive telehealth co-marketing collaboration with Halozyme’s wholly-owned subsidiary, Antares Pharma, Inc., for XYOSTED®, described as the only FDA-approved, once-weekly subcutaneous testosterone auto-injector. The Company said additional strategic partnerships and enterprise relationships are advancing toward execution in the second half of 2026.

LifeMD ended the quarter with $25.1 million in cash, no debt, and $30 million of additional liquidity under its revolving credit facility. The Company expects to return to positive adjusted EBITDA in the second half of 2026 and to exit the fourth quarter at an annualized revenue run rate of approximately $250 million and approximately $22 million of annualized adjusted EBITDA.

The Company revised its full-year 2026 guidance to revenue of $205.5 million to $212.5 million and adjusted EBITDA of negative $6.0 million to breakeven, including $2 million to $3 million of net launch costs for XYOSTED® in 2026. Management will host a conference call at 4:30 p.m. Eastern time today.

Management Commentary

“Revenue of $47.3 million came in within our guidance range, and while adjusted EBITDA finished below the range we guided to, it improved approximately 21% sequentially. Most importantly, we understand the drivers of the result and have already taken steps to improve performance in the second half. At the same time, the quarter included meaningful progress in reshaping the business around longer-duration members, branded therapies, pharmacy, insurance, and new partnerships. The near-term impact on profitability was greater than we anticipated, but the decisions we made during the quarter are already driving a substantial shift towards what we believe will be higher LTV subscribers,” said Justin Schreiber, Chairman and CEO of LifeMD.

“Our model remains simple: Quality Care. Quality Products. Quality Revenue. We are building around longer patient relationships and a more diversified acquisition model, with increasing contributions over time from pharmaceutical manufacturers, employers, insurers, Medicare, referrals, and cross-care within our existing patient base. Following the pricing change in weight management, the share of new patients selecting multi-month packages increased from approximately 25% year to date before the change to approximately 85% after it. We believe these longer-duration relationships can support better outcomes, stronger retention, higher lifetime value, and more predictable revenue over time.

“This transition to branded GLP-1 medications has weighed on near-term profitability, but it has produced a fundamentally stronger company that is more diversified. We are also encouraged by the progress we are seeing in Women’s Health, the launch of XYOSTED® with Halozyme, the continued expansion of our pharmacy, and the development of our pharmaceutical, enterprise, insurance, and Medicare channels. We expect to return to positive adjusted EBITDA in the second half and to exit 2026 at an annualized revenue run rate of approximately $250 million with approximately $22 million of annualized adjusted EBITDA. LifeMD has never been better positioned, and the second half of this year will begin to demonstrate what our expanding platform is capable of,” Mr. Schreiber said.

“The second quarter reflected the planned step-down in marketing investment we described on our last call, with selling and marketing expense declining $1.8 million sequentially and other general and administrative expenses declining by approximately $2.2 million,” said Atul Kavthekar, Chief Financial Officer of LifeMD. “Revenue aligned with our expectations in the quarter, and gross margin expanded to approximately 89%, driven by lower shipping and fulfillment costs, improved provider efficiency, and the continued scaling of our in-house pharmacy. Our recurring rebill base now represents approximately 84% of revenue and is the profit engine that funds our growth. We exited the quarter with $25.1 million in cash and no debt, and we amended our revolving credit facility, further strengthening our financial flexibility. As more patients choose longer-duration subscription plans and marketing spend declines in the second half, we expect cash to build through year-end.”

Second Quarter 2026 Financial Highlights

All comparisons are with the second quarter of 2025 on a continuing operations basis, excluding WorkSimpli, which was divested on November 4, 2025, and is reported as discontinued operations for all periods presented. Non-GAAP financial measures referenced below are defined and reconciled to the most directly comparable GAAP measures at the end of this press release.

Total revenue was $47.3 million, compared with $49.0 million in the prior-year period, reflecting the continued shift from compounded to branded GLP-1 therapies and lower upfront revenue associated with the Company’s pricing and mix decisions.

Approximately 84% of revenue was derived from recurring subscriptions.

The number of active subscribers increased 20% to approximately 356,000 at quarter end.

At quarter end, the number of Weight Management Program subscribers was approximately 108,000, up from just under 100,000 at the end of the first quarter of 2026.

Gross profit was $42.0 million, essentially flat with the prior-year period despite lower revenue. Gross margin expanded to approximately 89%, compared with 86% in the prior-year period, primarily due to lower shipping and fulfillment costs and the continued scaling of the Company’s affiliated pharmacy.

Selling and marketing expenses increased 27% year over year to $28.0 million, but declined $1.8 million from the first quarter of 2026, consistent with the planned sequential step-down in patient acquisition spend.

General and administrative expenses declined 5% to $13.6 million, led by lower employee expenses and legal and professional services fees.

GAAP net loss from continuing operations attributable to common stockholders was $7.9 million, or $0.16 per share, compared with a GAAP net loss from continuing operations attributable to common stockholders of $3.8 million, or $0.09 per share, in the prior-year period.

Adjusted EBITDA loss was approximately $3.5 million, compared with adjusted EBITDA of approximately $3.9 million in the prior-year period, reflecting elevated customer acquisition costs earlier in the quarter and lower upfront cash collection associated with the Company’s $39 introductory offer. Monthly performance improved as the quarter progressed.

Cash totaled $25.1 million as of June 30, 2026, and the Company had no debt at quarter end, with an undrawn $30 million revolving credit facility.

Positioned for a Strong Second Half

LifeMD said it enters the second half with improving acquisition trends, a growing recurring patient base, and a broader set of growth channels taking shape. Priorities for the remainder of 2026 include scaling longer-duration weight management memberships, expanding Women’s Health and the XYOSTED® collaboration, increasing pharmacy attachment, and advancing pharmaceutical, insurance, Medicare, employer, and enterprise relationships.

The Company said these initiatives should reduce reliance on paid media, deepen patient relationships, and support improving operating leverage and financial performance through year-end.

Financial Guidance

For the third quarter of 2026, LifeMD expects:

• Revenue of $48 million to $51 million.
• Adjusted EBITDA of negative $1 million to positive $2 million, returning to positive adjusted EBITDA as cost savings take hold and the Company’s recurring rebill base continues to build.

For full-year 2026, LifeMD expects:

• Revenue of $205.5 million to $212.5 million, compared with previous guidance of $220 million to $230 million.
• Adjusted EBITDA of negative $6.0 million to breakeven, compared with previous guidance of $12 million to $17 million.

The Company said its fourth-quarter 2026 guidance of $60 million to $64 million of revenue and $3 million to $6 million of adjusted EBITDA implies an annualized exit run rate of approximately $250 million of revenue and, before estimated XYOSTED® launch costs, approximately $22 million of continuing adjusted EBITDA.

Conference Call

LifeMD management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company’s financial results and outlook and answer questions. A live and archived webcast will be available in the Investors section of the Company’s website at ir.lifemd.com.

About LifeMD, Inc.

LifeMD® is a virtual care company focused on making healthcare more accessible, convenient, and affordable. Through its vertically integrated platform, LifeMD connects patients with a 50-state affiliated medical group, laboratory services, an in-house pharmacy, and a U.S.-based patient care center. The platform supports care across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. For more information, visit LifeMD.com.

Cautionary Note Regarding Forward-Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements in this news release may be identified by words such as “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” and comparable terminology referencing future periods. Examples include statements regarding financial outlook and guidance, short- and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, compliance with evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of these matters on future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. They are based on current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions. Because these statements relate to the future, they are subject to risks, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some outside the Company’s control. Actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, the “Risk Factors” identified in filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto.

Any forward-looking statement in this release is based on information available as of the date of the release. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law or regulation.

Investor Contact: ir@lifemd.com

Media Contact: press@lifemd.com

About the Use of Non-GAAP Financial Measures

To supplement financial information presented in accordance with GAAP, LifeMD uses adjusted EBITDA as a non-GAAP financial measure to clarify and enhance understanding of past performance. The Company believes this presentation enhances investors’ understanding of its financial performance and provides a useful metric for assessing operating performance period to period by excluding certain items it believes are not representative of core business operations. The Company also uses certain financial measures for business planning purposes and in measuring performance relative to competitors.

Adjusted EBITDA is defined as net loss attributable to LifeMD, Inc. common stockholders before interest, taxes, depreciation, amortization, extraordinary litigation costs, severance and restructuring costs, acquisition expenses, insurance acceptance readiness expenses, preferred stock dividends, stock-based compensation expense, net income from discontinued operations, and net income attributable to noncontrolling interests of discontinued operations. A reconciliation of adjusted EBITDA to net loss attributable to LifeMD, Inc. common stockholders, the most directly comparable GAAP measure, is provided in the release. The Company said adjusted EBITDA may differ from the use of the term by others in its industry and should not be considered an alternative to net loss before taxes, net loss per share, operating loss, or other GAAP performance measures.